The medical devices sector is typified by frequent change and innovation, in response to problems and issues faced by the healthcare industry. As a result, the sector has seen the emergence of several start-up medtech companies offering disruptive, cutting-edge solutions. Most of these are private companies, where data such as revenue is frequently not disclosed. National estimates for Galvanize Therapeutics sales in the US from 2016 to 2022, as well as year-on-year growth rates, can be viewed in GlobalData’s micro revenue report. Buy the report here.
Galvanize Therapeutics is a biopharmaceutical company that is involved in engineering, biology, and healthcare delivery to deliver life-changing solutions to patients and doctors. The company is developing technologies to treat several conditions in chronic bronchitis (COPD), cardiac arrhythmias, and caners for solid tumors. The major product pipeline includes airway disease for chronic bronchitis in Phase III; cardiac arrhythmias for persistent AF, and paroxysmal AF in Phase II and Phase I; cancer for lungs, hepatocellular carcinoma, renal cell carcinoma, and breast cancer in the preclinical stage. It also offers RheOx for chronic bronchitis, Centauri for paroxysmal atrial fibrillation, and Aliya for soft tissue ablation. Galvanize is headquartered in San Carlos, California, the US.
The key metrics of Galvanize Therapeutics related to marketed and pipeline products, ongoing clinical trials, active jobs and publications from 2022 are shown below:
As Galvanize Therapeutics is a privately held company, it is not required to disclose its financial information and there is no stock listed on an exchange. GlobalData has access to a proprietary data set containing invoice data from over 2,600 healthcare institutions in the US and is therefore able to use estimations of a company’s revenue and growth to value private companies such as Galvanize Therapeutics.
For a detailed understanding of the performance of Galvanize Therapeutics, buy the report here.